Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response

Sara Zafarnia, Jessica Bzyl-Ibach, Igor Spivak, Yongping Li, Susanne Koletnik, Dennis Doleschel, Anne Rix, Sibylle Pochon, Isabelle Tardy, Seena Koyadan, Marc van Zandvoort, Moritz Palmowski, Fabian Kiessling, Wiltrud Lederle*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)896-907
Number of pages12
JournalNeoplasia (Online)
Volume19
Issue number11
DOIs
Publication statusPublished - Nov 2017

Keywords

  • ENDOTHELIAL GROWTH-FACTOR
  • SQUAMOUS-CELL CARCINOMA
  • VEGFR2-TARGETED MICROBUBBLES
  • PERICYTE COVERAGE
  • CONTRAST AGENT
  • MOLECULAR US
  • PDGF-B
  • THERAPY
  • EXPRESSION
  • METASTASIS

Cite this

Zafarnia, S., Bzyl-Ibach, J., Spivak, I., Li, Y., Koletnik, S., Doleschel, D., Rix, A., Pochon, S., Tardy, I., Koyadan, S., van Zandvoort, M., Palmowski, M., Kiessling, F., & Lederle, W. (2017). Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response. Neoplasia (Online), 19(11), 896-907. https://doi.org/10.1016/j.neo.2017.08.009